26
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives: To describe the immunological responses and clinical outcome of coronavirus (SARS) infected healthcare workers (HCW) who had been administered with convalescent plasma as a treatment.

          Methods: Convalescent plasma (500 mL) was obtained from each of three SARS patients and transfused into the three infected HCW. Donors were blood type O and seronegative for hepatitis B and C, HIV, syphilis and human T-cell lymphotropic virus types I and II (HTLV-I and -II). Serum antibody (IgG) titre was >640. Apharesis was performed with a CS 3000 plus cell separator followed by the forming of the convalescent phase plasma. As part of the routine check with donated plasma, the convalescent plasma was confirmed free of residual SARS-CoV by RT–PCR. Serial serum samples obtained from the recipients of the convalescent plasma were collected to undertake real-time quantitative RT–PCR for SARS-CoV for direct measurement of viral concentration. Specific immunoglobulin IgM and IgG concentrations were titrated using an antigen microarray developed in-house.

          Results: Viral load dropped from 495 × 10 3, 76 × 10 3 or 650 × 10 3 copies/mL to zero or 1 copy/mL one day after transfusion. Anti-SARS-CoV IgM and IgG also increased in a time-dependent manner following transfusion. All three patients survived. One HCW became pregnant subsequently, delivering 13 months after discharge. Positive anti-SARS-CoV IgG was detected in the newborn. Passive transfer of anti-SARS-CoV antibody from the mother was considered as a possibility.

          Conclusions: All infected HCW whose condition had progressed severely and who had failed to respond to the available treatment, survived after transfusion with convalescent plasma.

          Related collections

          Author and article information

          Journal
          J Antimicrob Chemother
          J. Antimicrob. Chemother
          jac
          jac
          Journal of Antimicrobial Chemotherapy
          Oxford University Press
          0305-7453
          1460-2091
          November 2005
          23 September 2005
          : 56
          : 5
          : 919-922
          Author notes
          1Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 325, Cheng-Kung Road, Sec. 2, Neihu, Taipei, 114, Taiwan; 2Division of Clinical Pathology, Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 3Division of Clinical Research, National Health Research Institutes, Taipei, Taiwan; 4Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; 5Biochip R & D Center, School of Dentistry, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; 6Division of Infectious Diseases, Taipei Municipal Hoping Hospital, Taipei, Taiwan
          [* ]Corresponding author. Tel: +866-2-8792-7257; Fax: +866-2-8792-7258; E-mail: fychang@ 123456mail.ndmctsgh.edu.tw
          Article
          dki346
          10.1093/jac/dki346
          7110092
          16183666
          a9585b3f-f1d0-4d9e-a853-24ad05cbbf66
          © The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

          This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

          History
          : 31 August 2005
          : 23 June 2005
          : 25 August 2005
          : 30 August 2005
          Categories
          Original Articles

          Oncology & Radiotherapy
          sars,coronavirus,therapy
          Oncology & Radiotherapy
          sars, coronavirus, therapy

          Comments

          Comment on this article